Integra LifeSciences lowers revenue and earnings outlook for 2026
Integra LifeSciences (IART) reduced its 2026 revenue forecast to $1.634B-$1.654B from $1.654B-$1.695B, and adjusted EPS to $2.30-$2.40 from $2.40-$2.50, citing July flooding in Cincinnati. Q3 revenue is estimated at $410M-$412M, with adjusted EPS at $0.55-$0.59. The company expects $85M+ in Q3 operating cash flow and $190M-$200M for the year, with full recovery by Q2 2027. Shares fell 20.6% on Friday.
How this was made
The 30-second read
Why it matters
Guidance cut reflects material operational setbacks, driving a sharp share decline.
Market read
The guidance downgrade is a primary catalyst for the stock's recent 20% drop.
What to watch
Insurance recoveries and inventory buffers could mitigate earnings impact.
Background
Integra LifeSciences experienced a July flood at its Cincinnati facility, prompting supply disruptions.
Ticker impact
Integra LifeSciences cut its 2026 revenue and earnings guidance after flood‑related disruptions.
likely downward pressure as investors price in lower outlook
The new revenue range of $1.634‑$1.654 B and EPS of $2.30‑$2.40 are below prior guidance, prompting a 20% share drop.
Market effects
Medical‑technology sector may see broader scrutiny of supply‑chain risks.
U.S. healthcare stocks could face modest sell pressure.
Limited to investors with exposure to U.S. med‑tech equities.
Counterpoint
The flood may be a one‑off event; operations could rebound, making the stock oversold.
Key entities
- companyIntegra LifeSciences
Medical‑technology firm reporting guidance cut.
